Suchergebnisse - "Vergote, Ignace"

PubPharm (957)

1

Gene expression markers in peripheral blood and outcome in patients with platinum-resistant ovarian cancer : A study of the European GANNET53 consortium

enthalten in: International journal of cancer | 2024

von Obermayr, E. | Mohr, T. | Schuster, E. | +13

2

Normalized LST is an efficient biomarker for homologous recombination deficiency and Olaparib response in ovarian carcinoma

enthalten in: bioRxiv.org | 2024

von Christinat, Y. | Ho, L. | Clément, S. | +11

3

Clinical evaluation of a low-coverage whole-genome test for detecting homologous recombination deficiency in ovarian cancer

enthalten in: European journal of cancer (Oxford, England : 1990) | 2024

von Boidot, R. | Blum, M. | Wissler, M. | +21

4

Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer

enthalten in: Leukemia | 2024

von Arends, C. | Kopp, K. | Hablesreiter, R. | +18

5

ENGOT-EN20/GOG-3083/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma : rationale, methods, and trial design

enthalten in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society | 2024

von Vergote, I. | Perez Fidalgo, A. | Valabrega, G. | +18

6

Mirvetuximab soravtansine-gynx : first antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancer

enthalten in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society | 2024

von Bogani, G. | Coleman, R. | Vergote, I. | +8

7

Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial

enthalten in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society | 2024

von Lorusso, D. | Mouret-Reynier, M. | Harter, P. | +27

8

Olaparib Addition to Maintenance Bevacizumab Therapy in Ovarian Carcinoma With BRCA-Like Genomic Aberrations

enthalten in: JAMA network open | 2024

von Schouten, P. | Schmidt, S. | Becker, K. | +20

9

Progression-free survival and safety at 3.5 years of follow-up : results from the randomized phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer - a plain language summary

enthalten in: Future oncology (London, England) | 2024

von González-Martín, A. | Pothuri, B. | Vergote, I. | +15

10

Primary results of the AGO-Zervix-1 Study : A prospective, randomized phase III study to compare the effects of paclitaxel and topotecan with those of cisplatin and topotecan in the treatment of patients with recurrent and persistent cervical cancer

enthalten in: Gynecologic oncology | 2024

von Gass, P. | Thiel, F. | Häberle, L. | +17

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[96]